Drug Shortage Report for APO-RIVASTIGMINE
Report ID | 221729 |
Drug Identification Number | 02336715 |
Brand name | APO-RIVASTIGMINE |
Common or Proper name | RIVASTIGMINE |
Company Name | APOTEX INC |
Market Status | MARKETED |
Active Ingredient(s) | RIVASTIGMINE |
Strength(s) | 1.5MG |
Dosage form(s) | CAPSULE |
Route of administration | ORAL ORAL |
Packaging size | 100 BTL |
ATC code | N06DA |
ATC description | ANTI-DEMENTIA DRUGS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2024-03-05 |
Estimated end date | 2024-05-10 |
Actual end date | 2024-05-09 |
Shortage status | Resolved |
Updated date | 2024-05-10 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 150 SIGNET DRIVE TORONTO, ONTARIO CANADA M9L 1T9 |
Company contact information | Apotex Customer Service - 1-877-427-6839 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2024-05-10 | French | Compare |
v5 | 2024-05-10 | English | Compare |
v4 | 2024-03-22 | French | Compare |
v3 | 2024-03-22 | English | Compare |
v2 | 2024-03-08 | French | Compare |
v1 | 2024-03-08 | English | Compare |
Showing 1 to 6 of 6